Cocrystal Pharma Shares Drop 35% Following Phase 2a Study Extension Announcement

GuruFocus.com01-01

Phase 2a human challenge trial for the experimental influenza medication CC-42344 was extended by Cocrystal Pharma (COCP, Financials). Low infection rates among individuals exposed to the H3N2 virus ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2500889644?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-01-01 03:03","share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","id":"2500889644","market":"us","top_or_hot":-1,"title":"Cocrystal Pharma Shares Drop 35% Following Phase 2a Study Extension Announcement","media":"GuruFocus.com","content":"<div>\n<p>Phase 2a human challenge trial for the experimental influenza medication CC-42344 was extended by Cocrystal Pharma (COCP, Financials). Low infection rates among individuals exposed to the H3N2 virus ...</p>\n\n<a href=\"https://finance.yahoo.com/news/cocrystal-pharma-shares-drop-35-190339268.html\">Source Link</a>\n\n</div>\n","source":"yahoofinance","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Cocrystal Pharma Shares Drop 35% Following Phase 2a Study Extension Announcement</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCocrystal Pharma Shares Drop 35% Following Phase 2a Study Extension Announcement\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-01-01 03:03 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/cocrystal-pharma-shares-drop-35-190339268.html><strong>GuruFocus.com</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Phase 2a human challenge trial for the experimental influenza medication CC-42344 was extended by Cocrystal Pharma (COCP, Financials). Low infection rates among individuals exposed to the H3N2 virus ...</p>\n\n<a href=\"https://finance.yahoo.com/news/cocrystal-pharma-shares-drop-35-190339268.html\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4007","symbol_name":"制药","start_time":0,"source_url":"https://finance.yahoo.com/news/cocrystal-pharma-shares-drop-35-190339268.html","article_id":"2500889644","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2500889644","pubTimestamp":1735671819,"columns":[],"sourceInfo":{"source_id":"yahoofinance","name":"雅虎金融"},"weMediaInfo":null,"summary":"Phase 2a human challenge trial for the experimental influenza medication CC-42344 was extended by Cocrystal Pharma . Low infection rates among individuals exposed to the H3N2 virus strain presented difficulties for the research meant to assess the safety, tolerability, and antiviral efficacy of the medicine. This problem has postponed the gathering of significant antiviral data, hence the business asked the UK Medicines and Healthcare Products Regulatory Agency for permission to change a procedure.The news sharply dropped the stock price of Cocrystal Pharma; shares dropped almost 35% and closed at $2.10. Notwithstanding the setback, the business underlined the promise of CC-42444, which aims at a crucial stage in the influenza A virus replication. Early studies reveal a solid safety profile and the experimental medicine has showed great in vitro efficacy against resistant bacteria.Using its unique structure-based drug discovery system, Cocrystal Pharma is developing antiviral therapies","collect":0,"end_time":0,"defaultTopTitle":"yahoo.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4007":"制药","COCP":"Cocrystal Pharma, Inc."},"translate_title":"宣布2a期研究延期后，Cocrystal Pharma股价下跌35%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"COCP":0.9},"content_text":"Phase 2a human challenge trial for the experimental influenza medication CC-42344 was extended by Cocrystal Pharma (COCP, Financials). Low infection rates among individuals exposed to the H3N2 virus strain presented difficulties for the research meant to assess the safety, tolerability, and antiviral efficacy of the medicine. This problem has postponed the gathering of significant antiviral data, hence the business asked the UK Medicines and Healthcare Products Regulatory Agency for permission to change a procedure.\n\nWarning! GuruFocus has detected 2 Warning Sign with COCP.\n\nThe news sharply dropped the stock price of Cocrystal Pharma; shares dropped almost 35% and closed at $2.10. Notwithstanding the setback, the business underlined the promise of CC-42444, which aims at a crucial stage in the influenza A virus replication. Early studies reveal a solid safety profile and the experimental medicine has showed great in vitro efficacy against resistant bacteria.\nUsing its unique structure-based drug discovery system, Cocrystal Pharma is developing antiviral therapies for influenza, coronaviruses, and other viruses. With up to 650,000 fatalities yearly and billions in financial damages, influenza A still presents a major worldwide health concern, according to the healthcare company. With fast-acting, safe, effective treatments, the business hopes to solve these problems.This article first appeared on \nGuruFocus.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-2","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.30.2","shortVersion":"4.30.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2500889644"}